Satellos Bioscience Inc.

MSLE Nasdaq CIK: 0001421642

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Emerging growth company
State of Incorporation Canada (Federal Level)
Business Address ROYAL BANK PLAZA, S. TOWER, 200 BAY ST., TORONTO, A6, M5J 2J1
Mailing Address ROYAL BANK PLAZA, S. TOWER, 200 BAY ST., TORONTO, A6, M5J 2J1
Phone 416-708-0522
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
40-F Canadian company annual report March 27, 2026 View on SEC
6-K Foreign company current report March 27, 2026 View on SEC
6-K Foreign company current report March 10, 2026 View on SEC
6-K Foreign company current report February 24, 2026 View on SEC
6-K Foreign company current report February 19, 2026 View on SEC
6-K Foreign company current report February 18, 2026 View on SEC
6-K Foreign company current report February 17, 2026 View on SEC
6-K Foreign company current report February 12, 2026 View on SEC
6-K Foreign company current report February 10, 2026 View on SEC
6-K Foreign company current report February 10, 2026 View on SEC

Annual Reports

40-F March 27, 2026
  • Developing SAT-3247, a promising oral treatment for Duchenne muscular dystrophy (DMD).
  • Successfully raised $25 million USD in capital to fund ongoing clinical development.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.